All Patients (N = 30) | |
---|---|
Patients with any treatment-emergent AE, n (%) | 30 (100) |
Patients with any treatment-emergent serious AE, n (%) | 12 (40) |
Patients with a grade 3 treatment-related AE, n (%) | 0 |
Patients with a grade 4 treatment-related AE, n (%) | 0 |
Patients with a grade 5 treatment-related AE, n (%) | 1 (3) |
Incidence of treatment-related AEs, n (%) | 18 (60) |
Fatigue, all grades | 4 (13) |
Grade 1 | 3 (10) |
Grade 2 | 1 (3) |
Infusion-related reaction, all grades | 2 (7) |
Grade 1 | 2 (7) |
Pyrexia, all grades | 2 (7) |
Grade 1 | 2 (7) |
Decreased appetite, all grades | 2 (7) |
Grade 1 | 2 (7) |
Hypophosphataemia, all grades | 2 (7) |
Grade 2 | 2 (7) |
AE adverse event
*AEs occurring in in ≥5% of patients are shown